Please provide your email address to receive an email when new articles are posted on . Eyevance Pharmaceuticals has acquired worldwide licensing rights to Nexagon, a 30-base antisense oligomer ...
Transplanted autologous corneal stem cells successfully repaired corneal injuries in patients. Over 90% of patients achieved complete or partial success. The procedure proved safe with no serious ...
Shares of Kala Pharmaceuticals surged Wednesday after the small biotechnology company announced a drug candidate for a rare eye disease. The Food and Drug Administration has accepted Kala's ...
-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 -- -- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing, ...
-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing ---- KPI-012 demonstrated ...
Kala Pharmaceuticals, a biopharmaceutical company specializing in therapies for rare eye diseases, has a promising drug, KPI-012, in its pipeline for treating Persistent Corneal Epithelial Defect ...
Corneal defects often heal themselves, but serious injuries that are left untreated can result in inflammation, infection, ulceration and even blindness. A new study provides exciting evidence ...
Corneal defects often heal themselves, but serious injuries that are left untreated can result in inflammation, infection, ulceration and even blindness. A new study provides exciting evidence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback